Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

23 Apr 2024

Abstract excerpt

PURPOSE: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose. PATIENTS AND METHODS: Subjects with ccRCC and progressive disease after at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer Research and Treatments
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38652038
DOI: 10.1158/1078-0432.ccr-23-3029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell CarcinomaPMID 38652038Read ↗

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma TreatmentSemantic proximity Read ↗

Current Landscape and the Potential Role of HIF and Selenium in Clear Cell Renal Cell Carcinoma TreatmentSemantic proximity Read ↗

Differential Effects of HIF2α Antagonist and HIF2α Silencing in Renal Cancer and Sensitivity to Repurposed DrugsSemantic proximity Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.Semantic proximity Read ↗

Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel–Lindau-Deficient Renal CancerSemantic proximity Read ↗

Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discoverySemantic proximity Read ↗

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in miceSemantic proximity Read ↗

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.Semantic proximity Read ↗

Targeting renal cell carcinoma with a HIF-2 antagonist.Semantic proximity Read ↗

Real-world efficacy and safety of belzutifan in patients with metastatic renal cell carcinoma: a multicenter retrospective study in JapanSemantic proximity Read ↗

Paraoxonase‐2 shRNA‐mediated gene silencing suppresses proliferation and migration, while promotes chemosensitivity in clear cell renal cell carcinoma cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.